Antibacterial treatment focused biopharma Antabio has appointed four new executives to strengthen its leadership team.
Gordon Waldron, the firm’s current chairman of the board, heads up Antabio’s finance department on a part time basis.
He joins the biopharma from finance and business development advice firm Sequoia Business Solutions, where he was chief executive officer.
Joining Waldron is Carole Sable, who will oversee Antabio’s clinical strategy.
Sable, has worked for numerous pharmaceutical companies including Vitae Pharmaceuticals, Revolution Medicines and Merck.
She said: “It is exciting to have the opportunity to work on the development of Antabio’s MBLi, which addresses a significant unmet need.”
Leading the firm’s business development dealings is Helmuth van Es, who joins the biopharma from biotech Galapagos, where he was founder.
Furthermore, David Lathbury, who was previously director of process chemistry at AstraZeneca and vice president of chemical development at AMRI, will manage all of Antabio’s CMC activities.
Marc Lemonnier, chief executive officer of Antabio, said: “We are thrilled to have attracted such high calibre talent and these new additions, along with expertise already in house, give Antabio the broad skill sets and high quality international leadership team needed as we embark on the next phase of our growth and move our antibacterial resistance pipeline towards the clinic.”